Nicox Completes Final Visit for NCX 470 Phase 3b Whistler Glaucoma Trial

Nicox SA has announced the completion of the final patient visit in its Phase 3b Whistler trial for NCX 470, focusing on intraocular pressure (IOP) reduction. Results are anticipated by May 2025. This clinical investigation involves a novel mechanism combining nitric oxide and prostaglandin analogs.

The Whistler trial included 18 healthy volunteers experiencing ocular hypertension, evaluating parameters such as trabecular meshwork outflow and episcleral venous pressure. Each participant underwent an 8-day, double-masked, placebo-controlled study.

Additionally, in the U.S.-based Denali Phase 3 trial, the last American participant has finished their visit, anticipating results by Q3 2025. NCX 470 is under license to Ocumension in China and Kowa in Japan, with plans for NDA submissions in both countries.